RecruitingNot ApplicableNCT07318896

Effect of Agar/Collagen-based Compounds on Osteoarticular Pain: Randomized Triple-blind Clinical Trial

Evaluation of the Effect of Agar and/or Collagen Based Compounds on Osteoarticular Pain. A Randomized, Parallel, Placebo Controlled, Triple Blind Clinical Trial (AGARTROSIS)


Sponsor

Fundació Eurecat

Enrollment

80 participants

Start Date

Nov 10, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Joints-comprising bone, cartilage, ligaments, and synovial fluid-enable stable daily movement but may deteriorate with age, excess body weight, overuse, injury, or disease. Such degeneration, common from age 40 onward, underlies joint disorders like osteoarthritis, particularly in the knees, hips, hands, and spine, and is a major cause of chronic pain and disability. While antiinflammatory analgesics remain the standard approach to symptom control, they neither cure disease nor regenerate cartilage and can produce significant long-term adverse effects (gastrointestinal, hepatic, renal, and cardiovascular). These limitations motivate interest in natural or complementary strategies with safer profiles. Within this context, marine algae, especially agar derived from red seaweed, have attracted attention for potential intestinal, metabolic, and joint benefits, aided by their fiber content. Another promising option is undenatured type II collagen (UC-II), the principal structural component of articular cartilage, whose endogenous production declines with age; clinical studies indicate that a daily intake of 40 mg UC-II can improve mobility, reduce pain, and enhance quality of life in individuals with osteoarthritis or exercise-related joint discomfort. Based on these considerations, an agar-agar supplement has been developed to relieve knee joint symptoms.


Eligibility

Min Age: 40 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Agar-Agar, Agar-Agar and undenatured collagen type II, and others for people with cartilage damage, inflammation, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTAgar-Agar

2.4 g of agar-agar (Rhodophyceae group) presented in capsule form will be given.

DIETARY_SUPPLEMENTAgar-Agar and undenatured collagen type II

2.4 g of agar- agar + 40 mg of undenatured collagen type II, presented in capsule form will be given.

DIETARY_SUPPLEMENTundenatured collagen type II

40 mg of undenatured collagen type II + 2.4 g of maltodextrin will be given in capsule form

DIETARY_SUPPLEMENTPlacebo

2.4 g Maltodextrin will be given in capsule form


Locations(1)

Eurecat, Technological Center of Catalonia, Nutrition and Health Unit

Reus, Tarragona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07318896


Related Trials